Blog
RSS FeedPosted by Michael Wonder on 16 Jan 2020
Withdrawal from the drug benefits on 1 February 2020
16 January 2020 - Iressa, Procoralan, Skinoren Cream, Vesicare and Reyataz are among the medicines that are withdrawn from the drug ...
Posted by Michael Wonder on 15 Jan 2020
TLV has decided to reconsider the subsidy for Xeljanz
14 January 2020 - When TLV decided that Xeljanz should be included in the high-cost protection, this was justified by the ...
Posted by Michael Wonder on 15 Jan 2020
TLV has decided to reconsider the subsidy for Olumiant
14 January 2020 - When TLV decided that Olumiant should be included in the high-cost protection, this was justified by the ...
Posted by Michael Wonder on 18 Dec 2019
Health economic assessment of Kyprolis in combination with Revlimid and dexamethasone
17 December 2019 - TLV has developed a new health economic knowledge base for the regions of the drug Kyprolis ...
Posted by Michael Wonder on 16 Dec 2019
The reimbursement for medicines will continue to increase in 2019
13 December 2019 - According to TLV's forecast, the reimbursement from the side agreements is estimated to amount to SEK ...
Posted by Michael Wonder on 12 Dec 2019
Swedish prices for medicines among the lowest in Europe
11 December 2019 - Since 2014, the Dental and Pharmaceutical Benefits Agency, TLV, has conducted an annual international price comparison ...
Posted by Michael Wonder on 28 Nov 2019
Agneta Karlsson new Director General at TLV
28 November 2019 - Today the Government has appointed Agneta Karlsson as new Director General of the Authority Dental Care and ...
Posted by Michael Wonder on 26 Nov 2019
Zejula is included in the high-cost protection with limitation
25 November 2019 - Zejula (niraparib) is included in the high-cost, limited-subsidy protection from December 1, 2019. ...
Posted by Michael Wonder on 19 Nov 2019
Withdrawal from the drug benefits on 1 December
15 November 2019 - Below is a compilation of the medicines in different packaging sizes which, at the companies' own ...
Posted by Michael Wonder on 12 Nov 2019
Health economic assessment of Tecentriq for triple negative breast cancer
8 November 2019 - TLV has produced a health economic knowledge base for the county council for the drug Tecentriq (atezolizumab). ...
Posted by Michael Wonder on 31 Oct 2019
Parallel distributed or parallel imported Maviret and Viekirax remain in high cost protection
28 October 2019 - TLV has reconsidered the subsidy for parallel distributed or parallel imported Maviret and Viekirax and decided ...
Posted by Michael Wonder on 23 Oct 2019
The district court rejected an appeal against Darzalex
21 October 2019 - TLV's decision to reject the grant application for Darzalex was appealed to the Administrative Court in ...
Posted by Michael Wonder on 08 Jul 2019
Withdrawals from the drug benefits - August 2019
8 July 2019 - Etalpha 80 mg & 100 capsules, Leflunomide medac 15 mg & 30 tablets and Maviret 100 mg ...
Posted by Michael Wonder on 03 Jul 2019
Gefitinib in new exchange group
28 June 2019 - As of June, gefitinib is included as an exchange group on the list of period goods. ...
Posted by Michael Wonder on 03 Jul 2019
Joint evaluation report of sotagliflozin (Zynquista)
28 June 2019 - TLV, together with the corresponding authorities in the Netherlands, ZIN, and in Ireland, NCPE, have written ...